Tempest Historical Balance Sheet

TPST Stock

USD 0.82 0.01 1.85%

Trend analysis of Tempest Therapeutics balance sheet accounts such as Liabilities And Stockholders Equity of 70.9 M, Non Current Liabilities Total of 13 M, Total Liabilities of 22.6 M or Total Current Assets of 65.6 M provides information on Tempest Therapeutics' total assets, liabilities, and equity, which is the actual value of Tempest Therapeutics to its prevalent stockholders. By breaking down trends over time using Tempest Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tempest Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tempest Therapeutics is a good buy for the upcoming year.

Tempest Therapeutics Inventory

1.25 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

About Tempest Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Tempest Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Tempest Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tempest Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tempest currently owns. An asset can also be divided into two categories, current and non-current.

Tempest Therapeutics Balance Sheet Chart

At this time, Tempest Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 48.4 M in 2025, whereas Retained Earnings are likely to drop (156.2 M) in 2025.

Total Assets Total Current Liabilities Common Stock Total Equity Non Current Liabilities Total

Total Assets

Total assets refers to the total amount of Tempest Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tempest Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Tempest Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tempest Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from Tempest Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.At this time, Tempest Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 48.4 M in 2025, whereas Retained Earnings are likely to drop (156.2 M) in 2025.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	7.3M	9.4M	10.8M	9.6M
Total Assets	46.1M	51.6M	59.3M	70.9M

Total Current Liabilities Total Assets

Tempest Therapeutics balance sheet Correlations

	Total Assets	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Common Stock	Current Deferred Revenue	Short Long Term Debt Total	Net Receivables	Short Term Debt
Total Assets		0.73	-0.66	-0.72	0.62	0.75	-0.34	-0.17	0.99	0.71	0.78	0.33	0.77	0.31	0.59	0.92	-0.02	0.62	0.29	0.79	0.32	0.56	-0.06	-0.04	0.13	0.01
Total Current Liabilities	0.73		-0.55	-0.58	0.71	0.55	-0.17	0.06	0.71	0.93	0.43	0.37	0.31	0.35	0.4	0.52	0.21	0.14	0.75	0.6	0.4	0.15	-0.12	0.4	0.56	0.34
Net Debt	-0.66	-0.55		0.49	-0.88	-0.21	0.2	0.07	-0.69	-0.59	-0.5	0.03	-0.41	0.13	-0.45	-0.64	0.22	-0.08	-0.4	-0.4	0.03	-0.09	-0.13	0.16	-0.15	0.12
Retained Earnings	-0.72	-0.58	0.49		-0.54	-0.81	0.17	0.03	-0.7	-0.47	-0.48	-0.41	-0.48	-0.4	-0.89	-0.6	-0.17	-0.34	-0.11	-0.84	-0.4	-0.68	0.11	-0.13	0.11	-0.19
Cash	0.62	0.71	-0.88	-0.54		0.23	-0.09	0.08	0.6	0.61	0.34	0.37	0.15	0.27	0.51	0.44	0.23	-0.18	0.5	0.41	0.38	-0.07	-0.12	0.33	0.18	0.34
Common Stock Total Equity	0.75	0.55	-0.21	-0.81	0.23		-0.05	0.08	0.72	0.46	0.4	0.35	0.59	0.4	0.59	0.59	0.09	0.58	0.06	0.71	0.34	0.76	-0.12	0.05	-0.02	0.09
Non Current Liabilities Total	-0.34	-0.17	0.2	0.17	-0.09	-0.05		0.97	-0.36	-0.25	-0.81	0.11	-0.36	0.1	-0.33	-0.45	0.12	-0.38	-0.03	-0.61	0.07	-0.28	-0.05	0.2	-0.11	0.16
Total Liab	-0.17	0.06	0.07	0.03	0.08	0.08	0.97		-0.2	-0.03	-0.71	0.2	-0.29	0.18	-0.24	-0.34	0.18	-0.35	0.15	-0.48	0.16	-0.25	-0.07	0.3	0.03	0.24
Total Current Assets	0.99	0.71	-0.69	-0.7	0.6	0.72	-0.36	-0.2		0.72	0.8	0.23	0.8	0.21	0.56	0.94	-0.11	0.64	0.3	0.76	0.23	0.55	-0.04	-0.14	0.16	-0.07
Other Current Liab	0.71	0.93	-0.59	-0.47	0.61	0.46	-0.25	-0.03	0.72		0.51	0.1	0.4	0.08	0.25	0.6	-0.06	0.24	0.81	0.53	0.12	0.12	-0.03	0.12	0.68	0.08
Total Stockholder Equity	0.78	0.43	-0.5	-0.48	0.34	0.4	-0.81	-0.71	0.8	0.51		0.04	0.73	0.03	0.49	0.89	-0.22	0.71	0.13	0.82	0.05	0.55	0.09	-0.28	0.11	-0.24
Property Plant And Equipment Net	0.33	0.37	0.03	-0.41	0.37	0.35	0.11	0.2	0.23	0.1	0.04		-0.04	0.98	0.43	0.07	0.89	-0.13	-0.06	0.33	1.0	0.06	-0.6	0.78	-0.25	0.82
Accounts Payable	0.77	0.31	-0.41	-0.48	0.15	0.59	-0.36	-0.29	0.8	0.4	0.73	-0.04		-0.04	0.45	0.86	-0.41	0.84	-0.02	0.6	-0.07	0.63	0.17	-0.5	-0.05	-0.45
Non Current Assets Total	0.31	0.35	0.13	-0.4	0.27	0.4	0.1	0.18	0.21	0.08	0.03	0.98	-0.04		0.38	0.05	0.88	-0.07	-0.08	0.35	0.98	0.12	-0.6	0.77	-0.25	0.82
Non Currrent Assets Other	0.59	0.4	-0.45	-0.89	0.51	0.59	-0.33	-0.24	0.56	0.25	0.49	0.43	0.45	0.38		0.49	0.24	0.23	-0.07	0.78	0.42	0.56	-0.15	0.14	-0.27	0.2
Cash And Short Term Investments	0.92	0.52	-0.64	-0.6	0.44	0.59	-0.45	-0.34	0.94	0.6	0.89	0.07	0.86	0.05	0.49		-0.3	0.78	0.17	0.76	0.05	0.63	0.13	-0.34	0.09	-0.29
Common Stock Shares Outstanding	-0.02	0.21	0.22	-0.17	0.23	0.09	0.12	0.18	-0.11	-0.06	-0.22	0.89	-0.41	0.88	0.24	-0.3		-0.44	-0.08	0.09	0.91	-0.15	-0.73	0.86	-0.22	0.96
Short Term Investments	0.62	0.14	-0.08	-0.34	-0.18	0.58	-0.38	-0.35	0.64	0.24	0.71	-0.13	0.84	-0.07	0.23	0.78	-0.44		-0.15	0.58	-0.15	0.79	0.25	-0.52	-0.03	-0.51
Other Current Assets	0.29	0.75	-0.4	-0.11	0.5	0.06	-0.03	0.15	0.3	0.81	0.13	-0.06	-0.02	-0.08	-0.07	0.17	-0.08	-0.15		0.15	-0.03	-0.32	0.13	0.28	0.91	0.11
Other Stockholder Equity	0.79	0.6	-0.4	-0.84	0.41	0.71	-0.61	-0.48	0.76	0.53	0.82	0.33	0.6	0.35	0.78	0.76	0.09	0.58	0.15		0.33	0.72	0.0	0.07	0.05	0.07
Property Plant And Equipment Gross	0.32	0.4	0.03	-0.4	0.38	0.34	0.07	0.16	0.23	0.12	0.05	1.0	-0.07	0.98	0.42	0.05	0.91	-0.15	-0.03	0.33		0.04	-0.63	0.8	-0.21	0.85
Common Stock	0.56	0.15	-0.09	-0.68	-0.07	0.76	-0.28	-0.25	0.55	0.12	0.55	0.06	0.63	0.12	0.56	0.63	-0.15	0.79	-0.32	0.72	0.04		0.08	-0.32	-0.3	-0.2
Current Deferred Revenue	-0.06	-0.12	-0.13	0.11	-0.12	-0.12	-0.05	-0.07	-0.04	-0.03	0.09	-0.6	0.17	-0.6	-0.15	0.13	-0.73	0.25	0.13	0.0	-0.63	0.08		-0.38	0.21	-0.73
Short Long Term Debt Total	-0.04	0.4	0.16	-0.13	0.33	0.05	0.2	0.3	-0.14	0.12	-0.28	0.78	-0.5	0.77	0.14	-0.34	0.86	-0.52	0.28	0.07	0.8	-0.32	-0.38		0.13	0.86
Net Receivables	0.13	0.56	-0.15	0.11	0.18	-0.02	-0.11	0.03	0.16	0.68	0.11	-0.25	-0.05	-0.25	-0.27	0.09	-0.22	-0.03	0.91	0.05	-0.21	-0.3	0.21	0.13		-0.07
Short Term Debt	0.01	0.34	0.12	-0.19	0.34	0.09	0.16	0.24	-0.07	0.08	-0.24	0.82	-0.45	0.82	0.2	-0.29	0.96	-0.51	0.11	0.07	0.85	-0.2	-0.73	0.86	-0.07

Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	22.9M	73.2M	46.1M	51.6M	59.3M	70.9M
Total Current Liabilities	3.2M	20.0M	7.3M	9.4M	10.8M	9.6M
Net Debt	(16.4M)	(33.3M)	(9.1M)	(18.6M)	(16.7M)	(17.5M)
Retained Earnings	(71.8M)	(100.1M)	(135.8M)	(165.3M)	(148.7M)	(156.2M)
Cash	18.8M	51.8M	31.2M	39.2M	45.1M	35.9M
Liabilities And Stockholders Equity	22.9M	73.2M	46.1M	51.6M	59.3M	70.9M
Non Current Liabilities Total	88.4M	17.1M	20.7M	15.4M	17.7M	13.0M
Total Liab	91.7M	37.1M	28.0M	24.8M	28.6M	22.6M
Total Current Assets	19.8M	69.0M	33.0M	40.4M	46.4M	65.6M
Other Current Liab	1.4M	16.2M	3.3M	3.3M	3.8M	7.2M
Total Stockholder Equity	(68.8M)	36.1M	18.1M	26.8M	24.1M	37.9M
Property Plant And Equipment Net	3.0M	4.2M	12.7M	10.8M	12.4M	13.0M
Accounts Payable	1.1M	991K	1.1M	845K	760.5K	1.4M
Non Current Assets Total	3.0M	4.3M	13.1M	11.2M	12.9M	13.6M
Non Currrent Assets Other	51K	111K	429K	448K	515.2K	405.2K
Cash And Short Term Investments	18.8M	51.8M	31.2M	39.2M	35.3M	48.4M
Common Stock Shares Outstanding	31.2K	3.8M	11.5M	15.4M	17.7M	18.6M
Other Current Assets	745K	17.1M	1.4M	1.1M	1.3M	1.2M
Other Stockholder Equity	(170.9M)	136.2M	153.9M	192.0M	172.8M	130.6M
Property Plant And Equipment Gross	2.2M	5.0M	12.7M	11.8M	13.6M	14.3M
Common Stock	15K	7K	11K	22K	19.8K	16.1K
Short Long Term Debt Total	2.4M	18.5M	22.1M	20.7M	23.8M	12.6M
Net Receivables	1.3M	260K	15M	450K	517.5K	491.6K
Short Term Debt	712K	2.9M	2.8M	5.2M	6.0M	6.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tempest Historical Balance Sheet

Tempest Therapeutics Inventory

1.25 Million

About Tempest Balance Sheet Analysis

Tempest Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Common Stock Total Equity

Tempest Therapeutics balance sheet Correlations

Tempest Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tempest Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Tempest Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.98	Non Current Assets Total
Total Liab	+ 0.97	Non Current Liabilities Total
Short Term Debt	+ 0.96	Common Stock Shares Outstanding

Non Currrent Assets Other	- 0.89	Retained Earnings
Cash	- 0.88	Net Debt
Other Stockholder Equity	- 0.84	Retained Earnings
Total Stockholder Equity	- 0.81	Non Current Liabilities Total
Common Stock Total Equity	- 0.81	Retained Earnings
Short Term Debt	- 0.73	Current Deferred Revenue